Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resistant Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01042028
What this trial is testing

A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Per Pfeiffer 39
Early research (Phase 1)Study completedNCT00100139
What this trial is testing

Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer

Who this might be right for
Neoplasm
INSYS Therapeutics Inc 48
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Large-scale testing (Phase 3)UnknownNCT01224405
What this trial is testing

Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy

Who this might be right for
Advanced Prostate Cancer
University of Turin, Italy 600
Testing effectiveness (Phase 2)UnknownNCT04375956
What this trial is testing

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 100
Early research (Phase 1)Ended earlyNCT05107739
What this trial is testing

DeTIL-0255 in Adults With Advanced Malignancies

Who this might be right for
Platinum-resistant Ovarian CancerEndometrial CancerCervical Cancer
Nurix Therapeutics, Inc. 5
Testing effectiveness (Phase 2)Study completedNCT02125357
What this trial is testing

Sequencing Abiraterone and Enzalutamide in mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
British Columbia Cancer Agency 202
Large-scale testing (Phase 3)Study completedNCT03016312
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Hoffmann-La Roche 759
Testing effectiveness (Phase 2)Ended earlyNCT03741712
What this trial is testing

SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Study completedNCT01718353
What this trial is testing

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Sanofi 63
Not applicableStudy completedNCT07450157
What this trial is testing

Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 6,448
Testing effectiveness (Phase 2)Study completedNCT03081702
What this trial is testing

The Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

Who this might be right for
Platinum-resistant Epithelial Ovarian Cancer
University Health Network, Toronto 13
Large-scale testing (Phase 3)Study completedNCT02959749
What this trial is testing

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Who this might be right for
Progression Free Survival
Qingdao Central Hospital 147
Large-scale testing (Phase 3)Study completedNCT00276276
What this trial is testing

Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer

Who this might be right for
Lung Cancer, Small Cell
GlaxoSmithKline 141
Early research (Phase 1)Study completedNCT03136640
What this trial is testing

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
Modra Pharmaceuticals 23
Testing effectiveness (Phase 2)Study completedNCT00109096
What this trial is testing

Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy

Who this might be right for
Ovarian NeoplasmsPrimary Peritoneal Cancer
Eli Lilly and Company 100
Very early researchLooking for participantsNCT06632860
What this trial is testing

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

Who this might be right for
Iodine-resistant Thyroid CancerMeningiomaNETs
Peking Union Medical College Hospital 40
Not applicableEnded earlyNCT00631059
What this trial is testing

Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients

Who this might be right for
Leukemia
University of California, Irvine 40
Testing effectiveness (Phase 2)Study completedNCT00661180
What this trial is testing

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

Who this might be right for
Chronic Myelogenous Leukemia
Bayer 10
Next Page